Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
04:22pm, Monday, 27'th Jan 2025
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferie
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance
04:15pm, Monday, 27'th Jan 2025
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
The Stock Market Is Overbought and Insiders Are Selling – Grab These 5 High-Yield Blue Chips Now
10:34am, Monday, 27'th Jan 2025
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant income stream and have massive total return potential.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
10:06am, Monday, 27'th Jan 2025
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
12:00pm, Sunday, 26'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advise
Why Traders Are Buying the Dip on Johnson & Johnson Stock
07:38am, Saturday, 25'th Jan 2025
It is no secret that the defensive names in the stock market today, the ones not known for their hot price action or wild return potential, have been the lackluster segment of the financial markets la
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
06:17am, Saturday, 25'th Jan 2025
The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in t
Best 5 dividend aristocrat stocks to buy and hold
06:05am, Saturday, 25'th Jan 2025
Dividend aristocrats, or companies that have paid and raised dividends for at least 25 years are some of the best value stocks to buy and hold. Many of them have solid balance sheets and a long record
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning pos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
12:00pm, Friday, 24'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advise
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
What's Next For JNJ Stock After An Upbeat Q4?
06:30am, Friday, 24'th Jan 2025
Johnson & Johnson (NYSE: JNJ) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.04
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025
04:51am, Friday, 24'th Jan 2025
With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers countless ways for investors to grow their wealth. Though there's no one-size-fits-all b
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
03:02pm, Thursday, 23'rd Jan 2025
On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.
